Vanessa Biotech registers VR-AD-1005, a novel antidiarrheal investigational drug, for Phase II clinical trial with the Pan African Clinical Trials Registry for treatment of severe diarrhea of cholera.
Vanessa Biotech, the Hamden, Conn. based global biomedical company dedicated to making an impact on healthcare markets, has registered VR-AD-1005, a novel antidiarrheal investigational drug, with the Pan African Clinical Trials Registry (PACTR) system, as of June 21, 2021. The drug will be studied for the innovative treatment of severe diarrhea of cholera, heralding a pipeline of drugs developed in hopes of neutralizing the lethal diarrhea of cholera as well as rotaviral diarrhea and traveler’s diarrhea. VR-AD-1005 is intended to work by reducing the volume of liquid stool produced by the intestine when suffering from the diarrheal pathogen. The drug works within the intestine without affecting its motility and does not induce constipation. If successful—unlike other antidiarrheal medications—VR-AD-1005 will be the first symptomatic medication to treat severe secretory diarrhea. “Our unique approach to treatment of diarrhea concentrates on solving the problem of continuous removal of antidiarrheal medications with enormous volume of stool in patients suffering from acute watery diarrhea. This problem is known as convective washout, and it is recognized as the major factor limiting efficacy of oral antidiarrheal medicines. Vanessa Biotech is the first company that has developed a solution for it,” according to Dr. Dmitry Kravtsov, Vice President of Research and Development at Vanessa Biotech.
* These claims are based on preclinical studies and observed results in clinical trials to date. As clinical trials have not been completed, there can be no definitive proof these claims will ultimately be proven to be factual.
About Vanessa Biotech
Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain and Germany in addition to its Hamden, Conn. corporate campus.
Contact Information
Vanessa Biotech
P.O. Box 185755
Hamden, Conn. 06518 USA
+1 203 836 8424